By Sneha S K and Sahil Pandey
Dec 31 (Reuters) - The U.S. Food and Drug Administration has declined to approve Corcept Therapeutics' drug for the treatment of a rare hormonal disorder, the company said on Wednesday.
Shares of the drugmaker were down 48% at $36.41.
The company said the FDA could not arrive at a favorable benefit-risk assessment for the hormone-blocking oral treatment, known as relacorilant, without Corcept providing additional evidence of effectiveness.
The company was seeking approval for relacorilant as a treatment for patients with hypertension secondary to hypercortisolism.
"FDA's request for additional data may require additional trials, significantly dimming Corcept's outlook in Cushings," said Truist analyst Joon Lee.
Hypercortisolism, also known as Cushing's syndrome, occurs when the body is exposed to high cortisol activity.
Corcept had submitted trial data that showed that relacorilant made improvements in a wide array of hypercortisolism's signs and symptoms.
"We will meet with the FDA as soon as possible to discuss the best path forward," said Joseph Belanoff, Corcept's CEO.
Main symptoms of hypercortisolism include a fatty hump between the shoulders, a rounded face, and pink or purple stretch marks on the skin. People with Cushing's also experience diabetes, high blood pressure, muscle weakness and immune suppression.
Relacorilant is a selective cortisol modulator designed to block the effects of cortisol, while avoiding certain off‑target hormonal effects.
"Given the company had opportunities to address FDA's concerns during mid and late-stage reviews, it's unclear if any further dialogue can resolve the review issues without additional trials," Lee added.
Corcept is also studying the drug in a variety of serious disorders including ovarian and prostate cancer. Its other drug known as Korlym is approved to treat high blood sugar caused by hypercortisolism in adults with endogenous Cushing's syndrome.
Other approved treatments for Cushing's syndrome include Isturisa by Recordati and Xeris Biopharma's Recorlev.
(Reporting by Sahil Pandey and Sneha S K in Bengaluru; Editing by Shailesh Kuber)
LATEST POSTS
- 1
Ukrainian foreign minister appeals for funds for drones - 2Historic underwater structure discovered by divers off French coast
- 3The Reduced Portage Horse: An Inheritance Reconsidered for Present day Experience
- 4Supercharge Your Remote Work Arrangement with These Game-Changing Instruments
- 5EU calls on Western Balkans to step up reforms for membership
- Watch Blue Origin's huge New Glenn rocket ace its epic landing on a ship at sea (video)
- Eating ultra-processed foods could raise precancerous polyp risk for women under 50, according to research
- Bismuth’s haredi draft bill won’t change enlistment, IDI expert tells 'Post'
- The Developing Nearby Food Development and Its Advantages
- Russia Creates New Military Branch Dedicated To Drone Warfare
- West Antarctica’s history of rapid melting foretells sudden shifts in continent’s ‘catastrophic’ geology
- Find the Effect of Web-based Entertainment on Psychological wellness: Exploring the Advanced Scene Securely
- One perk to marrying Richard Marx later in life? 'We don't have time' for stupid arguments, says Daisy Fuentes.
- 6 Fun Urban areas For Seniors To Travel
